Rheumatoid Arthritis Market to Grow by CAGR of 7.2% Through 2016, Says FirstWord
24 Sep 2012 • by Natalie Aster
In 2011, worldwide sales of Rheumatoid Arthritis (RA) drugs totalled over $16.5 billion, representing an overall compound annual growth rate (CAGR) of 19 percent over 2006 to 2011, more than a two-fold increase from the $7.4 billion valuation worldwide (company reported sales). Drivers for this growth included continued uptake of key anti-Tumour Necrosis Factor (anti-TNF) brands, significant price increases in the US, an increasing elderly and diagnosed patient population and the launch of other drugs with alternative mechanisms of action.
The new report "Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module" by GBI Research states that there has been very little resistance to this growth, and the prominent status of the RA market is also due to the fact that all of the major brands are biological and remain under patent protection.
Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module
Published: August, 2012
Price: US$ 4.995,00
The worldwide RA market is set to grow by a CAGR of 7.2 percent from $16.5 billion in 2011 to $23.3 billion in 2016. Main drivers will be the continued organic growth of the current products, in addition to launch of three new compounds - tofacitinib (Pfizer), fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) and secukinumab (AIN457; Novartis) - over the forecast period. However, the development and potential launch of biosimilars is anticipated to partially offset sales expansion. The first biosimilar anti-TNF is expected in 2014. As illustrated in Figure 1, the RA market growth is set continue at a slower rate compared to historical growth.
More information can be found in the report “Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module” by FirstWord.
To order the report or ask for sample pages contact [email protected]